Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Transposon Mutagenesis of Bacteroides fragilis.

Veeranagouda Y, Husain F, Wexler HM.

Methods Mol Biol. 2019;2016:105-116. doi: 10.1007/978-1-4939-9570-7_10.

PMID:
31197713
2.

CRISPR-Cas Systems in Bacteroides fragilis, an Important Pathobiont in the Human Gut Microbiome.

Tajkarimi M, Wexler HM.

Front Microbiol. 2017 Nov 23;8:2234. doi: 10.3389/fmicb.2017.02234. eCollection 2017.

3.

Novel large-scale chromosomal transfer in Bacteroides fragilis contributes to its pan-genome and rapid environmental adaptation.

Husain F, Tang K, Veeranagouda Y, Boente R, Patrick S, Blakely G, Wexler HM.

Microb Genom. 2017 Nov;3(11). doi: 10.1099/mgen.0.000136.

4.
5.

Deficiency of the ferrous iron transporter FeoAB is linked with metronidazole resistance in Bacteroides fragilis.

Veeranagouda Y, Husain F, Boente R, Moore J, Smith CJ, Rocha ER, Patrick S, Wexler HM.

J Antimicrob Chemother. 2014 Oct;69(10):2634-43. doi: 10.1093/jac/dku219. Epub 2014 Jul 14.

6.

Identification of genes required for the survival of B. fragilis using massive parallel sequencing of a saturated transposon mutant library.

Veeranagouda Y, Husain F, Tenorio EL, Wexler HM.

BMC Genomics. 2014 Jun 4;15:429. doi: 10.1186/1471-2164-15-429.

7.

Antianaerobic antimicrobials: spectrum and susceptibility testing.

Brook I, Wexler HM, Goldstein EJ.

Clin Microbiol Rev. 2013 Jul;26(3):526-46. doi: 10.1128/CMR.00086-12. Review.

8.

Two multidrug-resistant clinical isolates of Bacteroides fragilis carry a novel metronidazole resistance nim gene (nimJ).

Husain F, Veeranagouda Y, Hsi J, Meggersee R, Abratt V, Wexler HM.

Antimicrob Agents Chemother. 2013 Aug;57(8):3767-74. doi: 10.1128/AAC.00386-13. Epub 2013 May 28.

9.

Transposon mutagenesis of Bacteroides fragilis using a mariner transposon vector.

Veeranagouda Y, Husain F, Wexler HM.

Anaerobe. 2013 Aug;22:126-9. doi: 10.1016/j.anaerobe.2013.04.012. Epub 2013 May 7.

10.

Transposon mutagenesis of the anaerobic commensal, Bacteroides fragilis, using the EZ::TN5 transposome.

Veeranagouda Y, Husain F, Wexler HM.

FEMS Microbiol Lett. 2012 Aug;333(2):94-100. doi: 10.1111/j.1574-6968.2012.02602.x. Epub 2012 Jun 18.

11.

Pump it up: occurrence and regulation of multi-drug efflux pumps in Bacteroides fragilis.

Wexler HM.

Anaerobe. 2012 Apr;18(2):200-8. doi: 10.1016/j.anaerobe.2011.12.017. Epub 2012 Jan 10. Review.

PMID:
22266580
12.

Antimicrobial resistance and prevalence of resistance genes in intestinal Bacteroidales strains.

Nakano V, Nascimento e Silva Ad, Merino VR, Wexler HM, Avila-Campos MJ.

Clinics (Sao Paulo). 2011;66(4):543-7.

13.

Characteristics of Bacteroides fragilis lacking the major outer membrane protein, OmpA.

Wexler HM, Tenorio E, Pumbwe L.

Microbiology. 2009 Aug;155(Pt 8):2694-706. doi: 10.1099/mic.0.025858-0. Epub 2009 Jun 4.

PMID:
19497947
14.

Isolation and characterization of porins from Desulfovibrio piger and Bilophila wadsworthia: structure and gene sequencing.

Avidan O, Kaltageser E, Pechatnikov I, Wexler HM, Shainskaya A, Nitzan Y.

Arch Microbiol. 2008 Dec;190(6):641-50. doi: 10.1007/s00203-008-0416-0. Epub 2008 Aug 16.

PMID:
18709355
15.

Cytokine release and expression induced by OmpA proteins from the Gram-negative anaerobes, Porphyromonas asaccharolytica and Bacteroides fragilis.

Magalashvili L, Lazarovich S, Pechatnikov I, Wexler HM, Nitzan Y.

FEMS Immunol Med Microbiol. 2008 Jul;53(2):252-9. doi: 10.1111/j.1574-695X.2008.00423.x. Epub 2008 May 21.

16.

Presence of quorum-sensing systems associated with multidrug resistance and biofilm formation in Bacteroides fragilis.

Pumbwe L, Skilbeck CA, Wexler HM.

Microb Ecol. 2008 Oct;56(3):412-9. doi: 10.1007/s00248-007-9358-3. Epub 2008 Jan 11.

PMID:
18188535
17.

Bacteroides: the good, the bad, and the nitty-gritty.

Wexler HM.

Clin Microbiol Rev. 2007 Oct;20(4):593-621. Review.

18.
19.

Impact of anatomic site on growth, efflux-pump expression, cell structure, and stress responsiveness of Bacteroides fragilis.

Pumbwe L, Skilbeck CA, Wexler HM.

Curr Microbiol. 2007 Oct;55(4):362-5. Epub 2007 Jul 26.

PMID:
17882508
20.

BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis.

Pumbwe L, Chang A, Smith RL, Wexler HM.

Microb Drug Resist. 2007 Summer;13(2):96-101.

PMID:
17650960
21.

Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of Bacteroides fragilis.

Pumbwe L, Skilbeck CA, Nakano V, Avila-Campos MJ, Piazza RM, Wexler HM.

Microb Pathog. 2007 Aug-Sep;43(2-3):78-87. Epub 2007 Apr 20.

PMID:
17524609
22.

Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilis.

Pumbwe L, Wareham DW, Aduse-Opoku J, Brazier JS, Wexler HM.

Clin Microbiol Infect. 2007 Feb;13(2):183-189. doi: 10.1111/j.1469-0691.2006.01620.x.

23.
24.

The Bacteroides fragilis cell envelope: quarterback, linebacker, coach-or all three?

Pumbwe L, Skilbeck CA, Wexler HM.

Anaerobe. 2006 Oct-Dec;12(5-6):211-20. Epub 2006 Oct 10. Review.

PMID:
17045496
25.

Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis.

Pumbwe L, Glass D, Wexler HM.

Antimicrob Agents Chemother. 2006 Sep;50(9):3150-3.

26.

Adherence of Bilophila wadsworthia to cultured human embryonic intestinal cells.

Gerardo SH, Garcia MM, Wexler HM, Finegold SM.

Anaerobe. 1998 Feb;4(1):19-27.

PMID:
16887620
27.

Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.

Pumbwe L, Chang A, Smith RL, Wexler HM.

J Antimicrob Chemother. 2006 Sep;58(3):543-8. Epub 2006 Jul 12.

PMID:
16840432
28.

Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance.

Pumbwe L, Ueda O, Yoshimura F, Chang A, Smith RL, Wexler HM.

J Antimicrob Chemother. 2006 Jul;58(1):37-46. Epub 2006 Jun 6.

PMID:
16757501
29.
30.

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Wexler HM, Engel AE, Glass D, Li C.

Antimicrob Agents Chemother. 2005 Oct;49(10):4413-7.

31.

Sixteen homologs of the mex-type multidrug resistance efflux pump in Bacteroides fragilis.

Ueda O, Wexler HM, Hirai K, Shibata Y, Yoshimura F, Fujimura S.

Antimicrob Agents Chemother. 2005 Jul;49(7):2807-15.

32.

In vitro activity of ertapenem: review of recent studies.

Wexler HM.

J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii11-21. Review.

PMID:
15150179
33.

In vitro activities of faropenem against 579 strains of anaerobic bacteria.

Wexler HM, Molitoris D, St John S, Vu A, Read EK, Finegold SM.

Antimicrob Agents Chemother. 2002 Nov;46(11):3669-75.

34.

Outer-membrane pore-forming proteins in gram-negative anaerobic bacteria.

Wexler HM.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S65-71.

PMID:
12173111
35.

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

Roe DE, Finegold SM, Citron DM, Goldstein EJ, Wexler HM, Rosenblatt JE, Cox ME, Jenkins SG, Hecht DW.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S40-6.

PMID:
12173107
36.

Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

Roe DE, Finegold SM, Citron DM, Goldstein EJ, Wexler HM, Rosenblatt JE, Cox ME, Jenkins SG, Hecht DW.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S36-9.

PMID:
12173106
37.

Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.

Finegold SM, Flynn MJ, Rose FV, Jousimies-Somer H, Jakielaszek C, McTeague M, Wexler HM, Berkowitz E, Wynne B.

Clin Infect Dis. 2002 Aug 15;35(4):428-33. Epub 2002 Jul 24.

PMID:
12145727
38.

Activities of ABT-773 against microaerophilic and fastidious organisms.

Finegold SM, Molitoris D, Phan VT, Vaisanen ML, Wexler HM.

Antimicrob Agents Chemother. 2002 Aug;46(8):2716-9.

40.

In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.

Wexler HM, Molitoris E, Molitoris D, Finegold SM.

J Antimicrob Chemother. 2001 Apr;47(4):467-9.

PMID:
11266423
41.

Short-term benefit from oral vancomycin treatment of regressive-onset autism.

Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM.

J Child Neurol. 2000 Jul;15(7):429-35.

PMID:
10921511
42.

In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

Wexler HM, Molitoris D, Finegold SM.

Antimicrob Agents Chemother. 2000 Aug;44(8):2222-4.

43.

Current susceptibility patterns of anaerobic bacteria.

Wexler HM, Finegold SM.

Yonsei Med J. 1998 Dec;39(6):495-501. Review.

44.

In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

Wexler HM, Molitoris E, Molitoris D, Finegold SM.

Antimicrob Agents Chemother. 1998 Apr;42(4):984-6.

45.

Anaerobic susceptibility testing: where are we and where do we go from here?

Wexler HM.

Zentralbl Bakteriol. 1998 Jan;287(1-2):1-5. No abstract available.

PMID:
9532259
46.

Pore-forming molecules in gram-negative anaerobic bacteria.

Wexler HM.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S284-6. Review.

PMID:
9310708
47.

Susceptibility testing of anaerobes: old problems, new options?

Wexler HM, Molitoris E, Molitoris D.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S275-8. No abstract available.

PMID:
9310705
48.

Sources and antimicrobial susceptibilities of Campylobacter gracilis and Sutterella wadsworthensis.

Molitoris E, Wexler HM, Finegold SM.

Clin Infect Dis. 1997 Sep;25 Suppl 2:S264-5. No abstract available.

PMID:
9310700
49.

Present studies of therapy for anaerobic infections.

Finegold SM, Wexler HM.

Clin Infect Dis. 1996 Dec;23 Suppl 1:S9-14. Review.

PMID:
8953100
50.

In vitro susceptibility of anaerobes to quinolones in the United States.

Hecht DW, Wexler HM.

Clin Infect Dis. 1996 Dec;23 Suppl 1:S2-8.

PMID:
8953099

Supplemental Content

Loading ...
Support Center